[ad_1]
Original Caption: US Chemical Stocks Increased Significantly Affected by Moderna’s New Corona Vaccine
Sinopec News Network, according to the ICIS website, news Nov. 16. American drugmaker Moderna announced on Monday positive results from the third phase of the coronavirus vaccine trial, which pushed up world oil prices and most of the shares of publicly traded American chemical companies.
The company said in a statement that the third phase of its candidate vaccine study was tested in more than 30,000 participants in the United States and was 94.5% effective.
This is the second study on the coronavirus vaccine, which showed positive results within a few weeks.
US pharmaceutical giant Pfizer announced last week that its coronavirus vaccine developed in cooperation with German immunotherapy expert BioNTech, based on clinical trials, is at least 90% effective.
Moderna is working with the US Centers for Disease Control and Prevention (CDC), Operation Warp Speed, and McKesson, a US government-contracted coronavirus vaccine distributor.
The company said that by the end of 2020, they expect to have about 20 million doses of the drug in the United States market, and it is expected to produce 500 to 1 billion doses globally in 2021.
Stéphane Bancel, CEO of Moderna, said: “This positive interim analysis from our phase 3 study provides us with the first clinical validation to show that our vaccine can prevent Covid-19, including serious diseases.”
Wang Lei, translated from ICIS
The original text is as follows:
Gross values and shares of US chemistry rise after news of Moderna’s coronavirus vaccine
American drugmaker Moderna on Monday announced positive results from its phase 3 trials of a coronavirus vaccine, which boosted global oil prices and most of the shares of U.S.-listed chemical companies.
The company said in a statement that the phase 3 study of its vaccine candidate showed an efficacy of 94.5% when tested among more than 30,000 participants in the US.
This is the second study on a coronavirus vaccine to show positive results in as many weeks.
The US pharmaceutical company Pfizer announced last week that the coronavirus vaccine it is developing in partnership with German immunotherapy specialist BioNTech is at least 90% effective according to clinical trials.
Moderna is working with the US Centers for Disease Control and Prevention (CDC), Operation Warp Speed, and McKesson, a US government-contracted coronavirus vaccine distributor.
The company said that by the end of 2020, they expect to have about 20 million doses ready to ship in the US and is on track to manufacture 500 million to 1 billion doses globally in 2021.
“This positive interim analysis from our phase 3 study has given us the first clinical validation that our vaccine can prevent Covid-19 disease, including severe disease,” said Moderna CEO Stéphane Bancel.
Massive information, accurate interpretation, all in the Sina Finance APP
